CN202078559U - Hydrogel type testicular transdermal patch - Google Patents
Hydrogel type testicular transdermal patch Download PDFInfo
- Publication number
- CN202078559U CN202078559U CN 201120145095 CN201120145095U CN202078559U CN 202078559 U CN202078559 U CN 202078559U CN 201120145095 CN201120145095 CN 201120145095 CN 201120145095 U CN201120145095 U CN 201120145095U CN 202078559 U CN202078559 U CN 202078559U
- Authority
- CN
- China
- Prior art keywords
- hydrogel
- patch
- adhesive layer
- attached
- testicular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 16
- 230000002381 testicular Effects 0.000 title claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract description 35
- 239000012790 adhesive layer Substances 0.000 claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 239000010410 layer Substances 0.000 claims abstract description 10
- 239000000499 gel Substances 0.000 claims abstract description 9
- 239000003961 penetration enhancing agent Substances 0.000 claims abstract 2
- 230000001681 protective effect Effects 0.000 claims abstract 2
- 239000000463 material Substances 0.000 claims description 3
- 238000001647 drug administration Methods 0.000 claims 1
- 238000013271 transdermal drug delivery Methods 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 7
- 210000003491 skin Anatomy 0.000 abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000035699 permeability Effects 0.000 abstract description 2
- 238000012377 drug delivery Methods 0.000 abstract 1
- 238000009413 insulation Methods 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 210000000434 stratum corneum Anatomy 0.000 abstract 1
- 210000001550 testis Anatomy 0.000 description 11
- 239000000203 mixture Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- -1 alcohol compound Chemical class 0.000 description 8
- 206010021929 Infertility male Diseases 0.000 description 5
- 208000007466 Male Infertility Diseases 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000149 penetrating effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 230000021595 spermatogenesis Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical class CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- RZJRJXONCZWCBN-UHFFFAOYSA-N alpha-octadecene Natural products CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 206010003883 azoospermia Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940038384 octadecane Drugs 0.000 description 2
- 239000003507 refrigerant Substances 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZONLNQGAWNLFCS-UHFFFAOYSA-N 12-hydroxyoctadeca-2,4-dienoic acid Chemical compound CCCCCCC(O)CCCCCCC=CC=CC(O)=O ZONLNQGAWNLFCS-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960001518 levocarnitine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- CBFCDTFDPHXCNY-UHFFFAOYSA-N octyldodecane Natural products CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229940047670 sodium acrylate Drugs 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000000920 spermatogeneic effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229960001947 tripalmitin Drugs 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The utility model discloses a hydrogel type testicular transdermal patch, which comprises a backing layer. An adhesive layer which is used for drug delivery by being attached to skin comprises active drugs, molecular gel, hydrogel, penetration enhancer and the like and is attached to the backing layer, a protective film which is used for preventing drugs on the adhesive layer from running off and protecting adhesiveness of the adhesive layer is attached to the adhesive layer and is tearable for use. The novel transdermal patch compared with the traditional patch has the advantages that (1) compatibility with water-soluble and fat-soluble drugs is better, matrix drug loading capacity is high, the characteristics of multiple components and high dose of drug use can be satisfied, (2) the hydrogel patch generally has a water content of 50% and above and is easy for softening stratum corneum and beneficial to transdermal absorption of drugs, and (3) the hydrogel patch is fine in permeability, adhesiveness and thermal insulation. The hydrogel type testicular transdermal patch further has the advantages of low stimulus to skin, reusability for application, avoidance of tearing pain, none of residue and the like.
Description
Technical field:
This utility model relates to a kind of patch that contains the medicine for treatment thing, particularly a kind of transdermal test in vitro hydrogel patch that is used for the testis position for the treatment of male sterility, sexual dysfunction.
Background technology:
As everyone knows, testis and epididymis are that mankind spermatozoon takes place and sophisticated tissue, and spermatogenesis or dysmaturity will cause male sterility; With drug-induced spermatogenesis or dysmaturity then is an important measures of male contraception.
The general treatment of male sterility mainly is the oral formulations of various Drug therapys such as various trace elements such as levocarnitine, vitamin E and zinc, selenium, ATP injection etc.Low for gonad function, the unusual situation of hormonal readiness can adopt.As CC, HCG, MCG etc.
In addition, the treatment means etc. that also has various Chinese medicines and auxiliary procreation technology (artificial insemination, gamete transplant).
As the route of administration of medicine, modal is oral and injection, also is the mode of the present main administration of adopting in the treatment of azoospermia.Yet, also do not have at present the product of transdermal medicine for treating azoospermia or male sterility on the domestic market.
The utility model content:
This utility model provides a kind of transdermal test in vitro hydrogel patch that is used for the testis position for the treatment of male sterility, sexual dysfunction.This patch can be used for treating spermatogenesis and the spermioteleosis obstacle that causes because of sex hormones secretion deficiency or peroxide injury, and directly acts on the complex function that the drug transdermal that avoids conception and control birth of spermatid absorbs.Compare with the method for avoiding conception and controling birth with existing treatment means, have the Inherent advantage of hydrogel patch, a kind of means of administration of local organization of active is provided simultaneously.
Concrete technical scheme of the present utility model is as follows:
Aquogel type testis transdermal administration patch; it is characterized in that; comprise a backing layer; be attached with the attaching skin of forming by these existing material components of active medicine, molecular gel, hydrogel and penetrating agent that passes through on the described backing layer and come the adhesive-layer of administration; be attached with one on the described adhesive-layer again and be used for preventing that the adhesive-layer drug component runs off; and protection adhesive-layer viscosity, the protecting film that can throw off during use.
Certainly, the adhesive-layer of above-mentioned patch, wherein, active medicine comprises existing refrigerant cooling agent, hormone medicine, vitamin medicaments, anti-oxidation medicine or compound Chinese medicinal preparation.Molecular gel is by the gel factor, and solvent or their mixture are formed.Hydrogel comprises water-soluble base, water-insoluble substrate or their mixture.Penetrating agent comprises dimethyl sulfoxide, azone class, alcohol compound, volatile oil and/or their mixture.
Aquogel type testis transdermal administration patch described in the utility model is as a kind of novel transdermal administration dosage form, and the advantage of comparing it with traditional patch has:
1) better with the compatibility of water solublity, fat-soluble medicine, the substrate drug loading is big, can satisfy the medication characteristics of multicomponent, heavy dose;
2) hydrogel patch contains the moisture more than 50% usually, is easy to make horny layer softening, is beneficial to the Transdermal absorption of medicine;
3) water-setting agent patch has air permeability and good, cohesiveness and heat insulating ability.And have the zest of skin for a short time, and can stick repeatedly, take off to paste and do not have pain, advantages such as noresidue.Domestic do not have similar products like at present.
Description of drawings:
Further specify this utility model below in conjunction with the drawings and specific embodiments.
Fig. 1 is the structure chart of aquogel type testis transdermal administration patch described in the utility model.
The specific embodiment:
For technological means, creation characteristic that this utility model is realized, reach purpose and effect is easy to understand, below in conjunction with concrete diagram, further set forth this utility model.
As shown in Figure 1; aquogel type testis transdermal administration patch described in the utility model; comprise a backing layer; be attached with the attaching skin of forming by these current material components of active medicine, molecular gel, hydrogel and penetrating agent that passes through on the described backing layer and come the adhesive-layer of administration; be attached with one on the described adhesive-layer again and be used for preventing that the adhesive-layer drug component runs off; and protection adhesive-layer viscosity, the protecting film that can throw off during use.
Below specifically introduce the main component of adhesive-layer:
Active medicine comprises existing refrigerant cooling agent, hormone medicine, vitamin medicaments, anti-oxidation medicine or compound Chinese medicinal preparation.
Molecular gel is by the gel factor, and solvent or their mixture are formed.Wherein, the gel factor comprises the tertiary amine of ad hoc structure and quaternary amines organic compound thereof such as lecithin, N, N, N,-three octadecane amine, gallbladder steroid eicosane amine, the two octadecane amine of methyl, dioctadecyl dimethyl ammonium chloride, organic molecules such as cyclodextrin derivative class such as beta-cyclodextrin, derivative of fatty acid such as 12-hydroxy octadecadienoic acid and associated salts thereof, glyceryl monostearate, glyceryl tristearate, tripalmitin etc.Solvent comprises that alkanes, dimethyl sulfoxide (DMSO), second are fine, cellosolvo, 1-propanol, 1-amylalcohol, 1-capryl alcohol, 1,2-propylene glycol, silicone oil, 14/isopropyl palmitate etc.
Hydrogel comprises water-soluble base, water-insoluble substrate or their mixture.Such as the polyacrylic acid of various models, according to sodium acrylate, carbomer resin, polyvinylpyrrolidone, sodium carboxymethyl cellulose, methylcellulose, polyvinyl alcohol and/or their mixture.
Penetrating agent comprises dimethyl sulfoxide, azone class, alcohol compound, volatile oil and/or their mixture.
In addition, adhesive-layer also can add additive, and this additive component comprises Kaolin, starch, micropowder silica gel, aluminum chloride, Alumen, sodium alginate etc.; Solvent comprises deionized water, propylene glycol, glycerol, ethanol and/or their mixture.
According to this aquogel type testis transdermal administration patch of such scheme preparation, when reality was used, ingredient contained in the patch can enter corium through horny layer and epidermis, diffuses into blood capillary, is transferred to the body circulation.Even directly see through the various recipient cells (comprising testis spermatogenic cell and spermatid) that the scrotum epidermis enters testis tissue.
Clinical practice shows that with respect to modes such as oral and injections, the advantage of transdermal administration patch described in the utility model is:
1) can avoid the degraded of liver first-pass effect and gastrointestinal tract, make the effect of medicine not be subjected to the influence of gastrointestinal factors medicine;
2) can control medicine near constant release, absorb steadily relatively, avoid the repeatedly blood medicine peak valley undulatory property that causes of medication of other preparations;
3) prolong action time, reduce administration number of times;
4) can regulate dosage by changing the administration area, reduce individual variation, and independently medication of patient, also can stop at any time.
More than show and described ultimate principle of the present utility model and principal character and advantage of the present utility model.The technical staff of the industry should understand; this utility model is not restricted to the described embodiments; that describes in the foregoing description and the description just illustrates principle of the present utility model; under the prerequisite that does not break away from this utility model spirit and scope; this utility model also has various changes and modifications, and these changes and improvements all fall in claimed this utility model scope.The claimed scope of this utility model is defined by appending claims and equivalent thereof.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201120145095 CN202078559U (en) | 2011-05-09 | 2011-05-09 | Hydrogel type testicular transdermal patch |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201120145095 CN202078559U (en) | 2011-05-09 | 2011-05-09 | Hydrogel type testicular transdermal patch |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN202078559U true CN202078559U (en) | 2011-12-21 |
Family
ID=45339219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201120145095 Expired - Fee Related CN202078559U (en) | 2011-05-09 | 2011-05-09 | Hydrogel type testicular transdermal patch |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN202078559U (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112245385A (en) * | 2020-11-24 | 2021-01-22 | 段有才 | Gel and gel patch for scrotum as well as preparation method and application of gel and gel patch |
| CN118924537A (en) * | 2024-08-19 | 2024-11-12 | 上海鲁一细胞生物技术有限公司 | Exosome skin care patch and preparation device and method thereof |
-
2011
- 2011-05-09 CN CN 201120145095 patent/CN202078559U/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112245385A (en) * | 2020-11-24 | 2021-01-22 | 段有才 | Gel and gel patch for scrotum as well as preparation method and application of gel and gel patch |
| CN118924537A (en) * | 2024-08-19 | 2024-11-12 | 上海鲁一细胞生物技术有限公司 | Exosome skin care patch and preparation device and method thereof |
| CN118924537B (en) * | 2024-08-19 | 2025-04-15 | 上海鲁一细胞生物技术有限公司 | Exosome skin care patch and preparation device and method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023201712B2 (en) | Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof | |
| CN101378729B (en) | Compositions and methods for treating dermatological conditions | |
| EP0974350B1 (en) | External preparation containing tranilast and process for producing the same | |
| BR112016028961B1 (en) | COMPOSITION INCLUDING ELECTROTWISTED FIBERS, ITS PREPARATION METHOD AND KIT | |
| ES2504065T3 (en) | Stable Rasagiline Composition | |
| US7989496B2 (en) | Transdermal delivery of ketoprofen polar derivatives | |
| CN103432104B (en) | Transdermal patch containing pramipexole | |
| TR201808178T4 (en) | Compositions for transdermal delivery of active agents. | |
| CN101588789B (en) | Pharmaceutical compositions and methods for treating inflammation in cattle and other animals | |
| CN106074453B (en) | Glycolin gel plaster and preparation method thereof | |
| CN102258455A (en) | A kind of steroid hormone coating agent and preparation method thereof | |
| CN102218074B (en) | A transdermal patch containing paeoniflorin and glycyrrhetinic acid and its preparation method | |
| CN101530401A (en) | Compound transdermal patch for treating acute and chronic inflammatory pain | |
| ES2624557T3 (en) | Transdermal pharmaceutical compositions comprising a SERM | |
| JP2008530139A (en) | Device for delivering a TRPV1 agonist | |
| CN102379862B (en) | Spirosal-containing hydrophilic cataplasm | |
| CN202078559U (en) | Hydrogel type testicular transdermal patch | |
| CN103181894B (en) | Nabumetone spraying agent and preparation method | |
| CA3013751C (en) | Compositions and methods for treatment and prevention of pyrexia in horses | |
| TWI615151B (en) | Promote transdermal delivery | |
| CN105726586A (en) | External preparation of ginkgo biloba extract and preparation method and application of external preparation | |
| CN203090245U (en) | Male contraception gel sticker | |
| US9737603B1 (en) | Alcohol-based local anesthesia and associated use thereof | |
| CN104415024B (en) | Cataplasm containing Diclofenac, and combinations thereof and preparation method | |
| CN101401782A (en) | Doractin dashing agent and method of preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111221 Termination date: 20200509 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |